GNS joins forces with Dana-Farber, Mount Sinai to build myeloma computer models

The models, which were developed using the GNS’s supercomputer-driven Reverse Engineering and Forward Simulation (REFS) platform, will assist researchers in discovering novel therapies for the disease and determine the existing treatments for patients.

GNS CEO and co-founder Colin Hill said the company will apply its Big Data analytics platform to create a disease-specific computer model that will yield a new resource to the multiple myeloma research and clinical community.

"This collaboration with Dana-Farber and Mount Sinai will create models that will help transform the tremendous amount of data coming from new technologies, such as next-generation sequencing, into predictive computer models of disease progression and treatment response for scientists and clinicians," Hill added.

Institute for Genomics and Multiscale Biology director and Department of Genetics and Genomics Sciences chair person Eric Schadt said prior published work has shown that approaches like the REFS platform can develop integrated network models of disease that can be used to uncover novel drivers of disease.

"With the wealth of detailed biological data available in this project, we look forward to a close collaboration with GNS to build a predictive model to elucidate novel insights into this complex disease," Schadt added.